APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Ovarian Cancer Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metastatic Ovarian Cancer Drug Market Analysis and Forecast 2026-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchMetastatic Ovarian Cancer Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Ovarian Cancer Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Metastatic Ovarian Cancer Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Ovarian Cancer Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Ovarian Cancer Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Metastatic Ovarian Cancer Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Metastatic Ovarian Cancer Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metastatic Ovarian Cancer Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metastatic Ovarian Cancer Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metastatic Ovarian Cancer Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Metastatic Ovarian Cancer Drug include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc. and Sumitomo Dainippon Pharma Co., Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Metastatic Ovarian Cancer Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metastatic Ovarian Cancer Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Metastatic Ovarian Cancer Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metastatic Ovarian Cancer Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metastatic Ovarian Cancer Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Metastatic Ovarian Cancer Drug sales, projected growth trends, production technology, application and end-user industry.

Metastatic Ovarian Cancer Drug Segment by Company

Adgero Biopharmaceuticals Inc

Cellceutix Corporation

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Eisai Co., Ltd.

Metastatic Ovarian Cancer Drug Segment by Type

E-749

Crizotinib

LV-305

G-305

CMB-305

Others

Metastatic Ovarian Cancer Drug Segment by Application

Clinic

Hospital

Others

Metastatic Ovarian Cancer Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Ovarian Cancer Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Ovarian Cancer Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Ovarian Cancer Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Metastatic Ovarian Cancer Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Metastatic Ovarian Cancer Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metastatic Ovarian Cancer Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. E-749 Major Manufacturers Table 3. Crizotinib Major Manufacturers Table 4. LV-305 Major Manufacturers Table 5. G-305 Major Manufacturers Table 6. CMB-305 Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Others Major Manufacturers Table 12. Metastatic Ovarian Cancer Drug Industry Trends Table 13. Metastatic Ovarian Cancer Drug Industry Drivers Table 14. Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges Table 15. Metastatic Ovarian Cancer Drug Industry Restraints Table 16. Global Metastatic Ovarian Cancer Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Metastatic Ovarian Cancer Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Metastatic Ovarian Cancer Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2021-2026) Table 20. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2027-2032) Table 21. Global Metastatic Ovarian Cancer Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2026) & (K Units) Table 23. Global Metastatic Ovarian Cancer Drug Sales by Region (2027-2032) & (K Units) Table 24. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2021-2026) Table 25. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2027-2032) Table 26. Global Metastatic Ovarian Cancer Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Metastatic Ovarian Cancer Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Metastatic Ovarian Cancer Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Metastatic Ovarian Cancer Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Metastatic Ovarian Cancer Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Metastatic Ovarian Cancer Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Metastatic Ovarian Cancer Drug Manufacturers, Product Type & Application Table 34. Global Metastatic Ovarian Cancer Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Metastatic Ovarian Cancer Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Metastatic Ovarian Cancer Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2026) Table 41. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2027-2032) Table 42. Global Metastatic Ovarian Cancer Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 44. Global Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 45. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2026) Table 46. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2027-2032) Table 47. Global Metastatic Ovarian Cancer Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Metastatic Ovarian Cancer Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Metastatic Ovarian Cancer Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2026) Table 53. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2027-2032) Table 54. Global Metastatic Ovarian Cancer Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2026) Table 58. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2027-2032) Table 59. Global Metastatic Ovarian Cancer Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Metastatic Ovarian Cancer Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Adgero Biopharmaceuticals Inc Company Information Table 62. Adgero Biopharmaceuticals Inc Business Overview Table 63. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 65. Adgero Biopharmaceuticals Inc Recent Development Table 66. Cellceutix Corporation Company Information Table 67. Cellceutix Corporation Business Overview Table 68. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio Table 70. Cellceutix Corporation Recent Development Table 71. F. Hoffmann-La Roche Ltd. Company Information Table 72. F. Hoffmann-La Roche Ltd. Business Overview Table 73. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 75. F. Hoffmann-La Roche Ltd. Recent Development Table 76. Immune Design Corp. Company Information Table 77. Immune Design Corp. Business Overview Table 78. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio Table 80. Immune Design Corp. Recent Development Table 81. Millennium Pharmaceuticals Inc Company Information Table 82. Millennium Pharmaceuticals Inc Business Overview Table 83. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 85. Millennium Pharmaceuticals Inc Recent Development Table 86. MolMed S.p.A. Company Information Table 87. MolMed S.p.A. Business Overview Table 88. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio Table 90. MolMed S.p.A. Recent Development Table 91. Natco Pharma Limited Company Information Table 92. Natco Pharma Limited Business Overview Table 93. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio Table 95. Natco Pharma Limited Recent Development Table 96. Northwest Biotherapeutics, Inc. Company Information Table 97. Northwest Biotherapeutics, Inc. Business Overview Table 98. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 100. Northwest Biotherapeutics, Inc. Recent Development Table 101. Sumitomo Dainippon Pharma Co., Ltd. Company Information Table 102. Sumitomo Dainippon Pharma Co., Ltd. Business Overview Table 103. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 105. Sumitomo Dainippon Pharma Co., Ltd. Recent Development Table 106. VG Life Sciences, Inc. Company Information Table 107. VG Life Sciences, Inc. Business Overview Table 108. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 110. VG Life Sciences, Inc. Recent Development Table 111. Pfizer Inc. Company Information Table 112. Pfizer Inc. Business Overview Table 113. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 115. Pfizer Inc. Recent Development Table 116. Richter Gedeon Nyrt. Company Information Table 117. Richter Gedeon Nyrt. Business Overview Table 118. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio Table 120. Richter Gedeon Nyrt. Recent Development Table 121. Eisai Co., Ltd. Company Information Table 122. Eisai Co., Ltd. Business Overview Table 123. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 125. Eisai Co., Ltd. Recent Development Table 126. North America Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 129. North America Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 130. North America Metastatic Ovarian Cancer Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 131. North America Metastatic Ovarian Cancer Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 132. North America Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 133. North America Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 134. North America Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 135. North America Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 136. North America Metastatic Ovarian Cancer Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 137. North America Metastatic Ovarian Cancer Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 138. North America Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. North America Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. North America Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. North America Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 142. North America Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 143. North America Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 144. North America Metastatic Ovarian Cancer Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 145. North America Metastatic Ovarian Cancer Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 146. United States Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 147. Canada Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 148. Europe Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 151. Europe Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 152. Europe Metastatic Ovarian Cancer Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 153. Europe Metastatic Ovarian Cancer Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 154. Europe Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 157. Europe Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 158. Europe Metastatic Ovarian Cancer Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 159. Europe Metastatic Ovarian Cancer Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 160. Europe Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Europe Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. Europe Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. Europe Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 164. Europe Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 165. Europe Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 166. Europe Metastatic Ovarian Cancer Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 167. Europe Metastatic Ovarian Cancer Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 168. Germany Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 169. France Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 170. U.K. Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 171. Italy Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 172. Netherlands Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 173. China Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 174. China Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 175. China Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 176. China Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 177. China Metastatic Ovarian Cancer Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 178. China Metastatic Ovarian Cancer Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 179. China Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 180. China Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 181. China Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 182. China Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 183. China Metastatic Ovarian Cancer Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 184. China Metastatic Ovarian Cancer Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 185. Asia Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 186. Asia Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 187. Asia Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 188. Asia Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 189. Asia Metastatic Ovarian Cancer Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 190. Asia Metastatic Ovarian Cancer Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 191. Asia Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 192. Asia Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 193. Asia Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 194. Asia Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 195. Asia Metastatic Ovarian Cancer Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 196. Asia Metastatic Ovarian Cancer Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 197. Asia Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Asia Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 199. Asia Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 200. Asia Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 201. Asia Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 202. Asia Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 203. Asia Metastatic Ovarian Cancer Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 204. Asia Metastatic Ovarian Cancer Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 205. Japan Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 206. South Korea Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 207. India Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 208. Australia Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 209. China Taiwan Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 210. Southeast Asia Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 211. SAMEA Metastatic Ovarian Cancer Drug Revenue by Type (2021-2026) & (US$ Million) Table 212. SAMEA Metastatic Ovarian Cancer Drug Revenue by Type (2027-2032) & (US$ Million) Table 213. SAMEA Metastatic Ovarian Cancer Drug Sales by Type (2021-2026) & (K Units) Table 214. SAMEA Metastatic Ovarian Cancer Drug Sales by Type (2027-2032) & (K Units) Table 215. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 216. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 217. SAMEA Metastatic Ovarian Cancer Drug Revenue by Application (2021-2026) & (US$ Million) Table 218. SAMEA Metastatic Ovarian Cancer Drug Revenue by Application (2027-2032) & (US$ Million) Table 219. SAMEA Metastatic Ovarian Cancer Drug Sales by Application (2021-2026) & (K Units) Table 220. SAMEA Metastatic Ovarian Cancer Drug Sales by Application (2027-2032) & (K Units) Table 221. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 222. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 223. SAMEA Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 224. SAMEA Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 225. SAMEA Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 226. SAMEA Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 227. SAMEA Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 228. SAMEA Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 229. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 230. SAMEA Metastatic Ovarian Cancer Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 231. Brazil Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 232. Argentina Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 233. Chile Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 234. Colombia Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 235. Peru Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 236. Saudi Arabia Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 237. Israel Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 238. UAE Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 239. Turkey Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 240. Iran Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 241. Egypt Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Table 242. Key Raw Materials Table 243. Raw Materials Key Suppliers Table 244. Metastatic Ovarian Cancer Drug Distributors List Table 245. Metastatic Ovarian Cancer Drug Customers List Table 246. Research Programs/Design for This Report Table 247. Authors List of This Report Table 248. Secondary Sources Table 249. Primary Sources List of Figures Figure 1. Metastatic Ovarian Cancer Drug Image Figure 2. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Ovarian Cancer Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. E-749 Image Figure 5. Crizotinib Image Figure 6. LV-305 Image Figure 7. G-305 Image Figure 8. CMB-305 Image Figure 9. Others Image Figure 10. Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Metastatic Ovarian Cancer Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Others Image Figure 15. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Metastatic Ovarian Cancer Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Metastatic Ovarian Cancer Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Metastatic Ovarian Cancer Drug Sales (2021-2032) & (K Units) Figure 21. Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Metastatic Ovarian Cancer Drug Sales YoY (2021-2032) & (K Units) Figure 24. Europe Metastatic Ovarian Cancer Drug Sales YoY (2021-2032) & (K Units) Figure 25. China Metastatic Ovarian Cancer Drug Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Metastatic Ovarian Cancer Drug Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Metastatic Ovarian Cancer Drug Sales YoY (2021-2032) & (K Units) Figure 28. Global Metastatic Ovarian Cancer Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Metastatic Ovarian Cancer Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Metastatic Ovarian Cancer Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Metastatic Ovarian Cancer Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2032) Figure 37. Global Metastatic Ovarian Cancer Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Metastatic Ovarian Cancer Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2032) Figure 43. North America Metastatic Ovarian Cancer Drug Revenue Share by Type (2021-2032) Figure 44. North America Metastatic Ovarian Cancer Drug Sales Share by Type (2021-2032) Figure 45. North America Metastatic Ovarian Cancer Drug Revenue Share by Application (2021-2032) Figure 46. North America Metastatic Ovarian Cancer Drug Sales Share by Application (2021-2032) Figure 47. North America Metastatic Ovarian Cancer Drug Revenue Share by Country (2021-2032) Figure 48. North America Metastatic Ovarian Cancer Drug Sales Share by Country (2021-2032) Figure 49. Europe Metastatic Ovarian Cancer Drug Revenue Share by Type (2021-2032) Figure 50. Europe Metastatic Ovarian Cancer Drug Sales Share by Type (2021-2032) Figure 51. Europe Metastatic Ovarian Cancer Drug Revenue Share by Application (2021-2032) Figure 52. Europe Metastatic Ovarian Cancer Drug Sales Share by Application (2021-2032) Figure 53. Europe Metastatic Ovarian Cancer Drug Revenue Share by Country (2021-2032) Figure 54. Europe Metastatic Ovarian Cancer Drug Sales Share by Country (2021-2032) Figure 55. China Metastatic Ovarian Cancer Drug Revenue Share by Type (2021-2032) Figure 56. China Metastatic Ovarian Cancer Drug Sales Share by Type (2021-2032) Figure 57. China Metastatic Ovarian Cancer Drug Revenue Share by Application (2021-2032) Figure 58. China Metastatic Ovarian Cancer Drug Sales Share by Application (2021-2032) Figure 59. Asia Metastatic Ovarian Cancer Drug Revenue Share by Type (2021-2032) Figure 60. Asia Metastatic Ovarian Cancer Drug Sales Share by Type (2021-2032) Figure 61. Asia Metastatic Ovarian Cancer Drug Revenue Share by Application (2021-2032) Figure 62. Asia Metastatic Ovarian Cancer Drug Sales Share by Application (2021-2032) Figure 63. Asia Metastatic Ovarian Cancer Drug Revenue Share by Country (2021-2032) Figure 64. Asia Metastatic Ovarian Cancer Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Metastatic Ovarian Cancer Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Metastatic Ovarian Cancer Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Metastatic Ovarian Cancer Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Metastatic Ovarian Cancer Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Metastatic Ovarian Cancer Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Metastatic Ovarian Cancer Drug Sales Share by Country (2021-2032) Figure 71. Metastatic Ovarian Cancer Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Metastatic Ovarian Cancer Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • E-749
  • Crizotinib
  • LV-305
  • G-305
  • CMB-305
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Adgero Biopharmaceuticals Inc
  • Cellceutix Corporation
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals Inc
  • MolMed S.p.A.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • VG Life Sciences, Inc.
  • Pfizer Inc.
  • Richter Gedeon Nyrt.
  • Eisai Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metastatic Ovarian Cancer Drug Market by Type
  3. 1.2.1 Global Metastatic Ovarian Cancer Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 E-749
  5. 1.2.3 Crizotinib
  6. 1.2.4 LV-305
  7. 1.2.5 G-305
  8. 1.2.6 CMB-305
  9. 1.2.7 Others
  10. 1.3 Metastatic Ovarian Cancer Drug Market by Application
  11. 1.3.1 Global Metastatic Ovarian Cancer Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Hospital
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Metastatic Ovarian Cancer Drug Market Dynamics
  1. 2.1 Metastatic Ovarian Cancer Drug Industry Trends
  2. 2.2 Metastatic Ovarian Cancer Drug Industry Drivers
  3. 2.3 Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Ovarian Cancer Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Metastatic Ovarian Cancer Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Metastatic Ovarian Cancer Drug Revenue by Region
  3. 3.2.1 Global Metastatic Ovarian Cancer Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metastatic Ovarian Cancer Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Metastatic Ovarian Cancer Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Metastatic Ovarian Cancer Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Metastatic Ovarian Cancer Drug Sales by Region
  9. 3.4.1 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Metastatic Ovarian Cancer Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Metastatic Ovarian Cancer Drug Revenue by Manufacturers
  2. 4.1.1 Global Metastatic Ovarian Cancer Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Metastatic Ovarian Cancer Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metastatic Ovarian Cancer Drug Sales by Manufacturers
  6. 4.2.1 Global Metastatic Ovarian Cancer Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Metastatic Ovarian Cancer Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Metastatic Ovarian Cancer Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Metastatic Ovarian Cancer Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Metastatic Ovarian Cancer Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Metastatic Ovarian Cancer Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Metastatic Ovarian Cancer Drug Manufacturers, Product Type & Application
  13. 4.7 Global Metastatic Ovarian Cancer Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Metastatic Ovarian Cancer Drug Market CR5 and HHI
  16. 4.8.2 2025 Metastatic Ovarian Cancer Drug Tier 1, Tier 2, and Tier 3
5 Metastatic Ovarian Cancer Drug Market by Type
  1. 5.1 Global Metastatic Ovarian Cancer Drug Revenue by Type
  2. 5.1.1 Global Metastatic Ovarian Cancer Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Metastatic Ovarian Cancer Drug Sales by Type
  6. 5.2.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Ovarian Cancer Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Metastatic Ovarian Cancer Drug Price by Type
6 Metastatic Ovarian Cancer Drug Market by Application
  1. 6.1 Global Metastatic Ovarian Cancer Drug Revenue by Application
  2. 6.1.1 Global Metastatic Ovarian Cancer Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Metastatic Ovarian Cancer Drug Sales by Application
  6. 6.2.1 Global Metastatic Ovarian Cancer Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Metastatic Ovarian Cancer Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Metastatic Ovarian Cancer Drug Price by Application
7 Company Profiles
  1. 7.1 Adgero Biopharmaceuticals Inc
  2. 7.1.1 Adgero Biopharmaceuticals Inc Company Information
  3. 7.1.2 Adgero Biopharmaceuticals Inc Business Overview
  4. 7.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  6. 7.1.5 Adgero Biopharmaceuticals Inc Recent Developments
  7. 7.2 Cellceutix Corporation
  8. 7.2.1 Cellceutix Corporation Company Information
  9. 7.2.2 Cellceutix Corporation Business Overview
  10. 7.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio
  12. 7.2.5 Cellceutix Corporation Recent Developments
  13. 7.3 F. Hoffmann-La Roche Ltd.
  14. 7.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 7.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 7.3.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  18. 7.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 7.4 Immune Design Corp.
  20. 7.4.1 Immune Design Corp. Company Information
  21. 7.4.2 Immune Design Corp. Business Overview
  22. 7.4.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio
  24. 7.4.5 Immune Design Corp. Recent Developments
  25. 7.5 Millennium Pharmaceuticals Inc
  26. 7.5.1 Millennium Pharmaceuticals Inc Company Information
  27. 7.5.2 Millennium Pharmaceuticals Inc Business Overview
  28. 7.5.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  30. 7.5.5 Millennium Pharmaceuticals Inc Recent Developments
  31. 7.6 MolMed S.p.A.
  32. 7.6.1 MolMed S.p.A. Company Information
  33. 7.6.2 MolMed S.p.A. Business Overview
  34. 7.6.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio
  36. 7.6.5 MolMed S.p.A. Recent Developments
  37. 7.7 Natco Pharma Limited
  38. 7.7.1 Natco Pharma Limited Company Information
  39. 7.7.2 Natco Pharma Limited Business Overview
  40. 7.7.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio
  42. 7.7.5 Natco Pharma Limited Recent Developments
  43. 7.8 Northwest Biotherapeutics, Inc.
  44. 7.8.1 Northwest Biotherapeutics, Inc. Company Information
  45. 7.8.2 Northwest Biotherapeutics, Inc. Business Overview
  46. 7.8.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  48. 7.8.5 Northwest Biotherapeutics, Inc. Recent Developments
  49. 7.9 Sumitomo Dainippon Pharma Co., Ltd.
  50. 7.9.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
  51. 7.9.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
  52. 7.9.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  54. 7.9.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
  55. 7.10 VG Life Sciences, Inc.
  56. 7.10.1 VG Life Sciences, Inc. Company Information
  57. 7.10.2 VG Life Sciences, Inc. Business Overview
  58. 7.10.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  60. 7.10.5 VG Life Sciences, Inc. Recent Developments
  61. 7.11 Pfizer Inc.
  62. 7.11.1 Pfizer Inc. Company Information
  63. 7.11.2 Pfizer Inc. Business Overview
  64. 7.11.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  66. 7.11.5 Pfizer Inc. Recent Developments
  67. 7.12 Richter Gedeon Nyrt.
  68. 7.12.1 Richter Gedeon Nyrt. Company Information
  69. 7.12.2 Richter Gedeon Nyrt. Business Overview
  70. 7.12.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio
  72. 7.12.5 Richter Gedeon Nyrt. Recent Developments
  73. 7.13 Eisai Co., Ltd.
  74. 7.13.1 Eisai Co., Ltd. Company Information
  75. 7.13.2 Eisai Co., Ltd. Business Overview
  76. 7.13.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  78. 7.13.5 Eisai Co., Ltd. Recent Developments
8 North America
  1. 8.1 North America Metastatic Ovarian Cancer Drug Market Size by Type
  2. 8.1.1 North America Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
  5. 8.2 North America Metastatic Ovarian Cancer Drug Market Size by Application
  6. 8.2.1 North America Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
  9. 8.3 North America Metastatic Ovarian Cancer Drug Market Size by Country
  10. 8.3.1 North America Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Metastatic Ovarian Cancer Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Metastatic Ovarian Cancer Drug Market Size by Type
  2. 9.1.1 Europe Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
  5. 9.2 Europe Metastatic Ovarian Cancer Drug Market Size by Application
  6. 9.2.1 Europe Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
  9. 9.3 Europe Metastatic Ovarian Cancer Drug Market Size by Country
  10. 9.3.1 Europe Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Metastatic Ovarian Cancer Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Metastatic Ovarian Cancer Drug Market Size by Type
  2. 10.1.1 China Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  4. 10.1.3 China Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
  5. 10.2 China Metastatic Ovarian Cancer Drug Market Size by Application
  6. 10.2.1 China Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 10.2.3 China Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metastatic Ovarian Cancer Drug Market Size by Type
  2. 11.1.1 Asia Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
  5. 11.2 Asia Metastatic Ovarian Cancer Drug Market Size by Application
  6. 11.2.1 Asia Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
  9. 11.3 Asia Metastatic Ovarian Cancer Drug Market Size by Country
  10. 11.3.1 Asia Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Metastatic Ovarian Cancer Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metastatic Ovarian Cancer Drug Market Size by Type
  2. 12.1.1 SAMEA Metastatic Ovarian Cancer Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Metastatic Ovarian Cancer Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Metastatic Ovarian Cancer Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Metastatic Ovarian Cancer Drug Market Size by Application
  6. 12.2.1 SAMEA Metastatic Ovarian Cancer Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Metastatic Ovarian Cancer Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Metastatic Ovarian Cancer Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Metastatic Ovarian Cancer Drug Market Size by Country
  10. 12.3.1 SAMEA Metastatic Ovarian Cancer Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Metastatic Ovarian Cancer Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Metastatic Ovarian Cancer Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Metastatic Ovarian Cancer Drug Value Chain Analysis
  2. 13.1.1 Metastatic Ovarian Cancer Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Metastatic Ovarian Cancer Drug Production Mode & Process
  6. 13.2 Metastatic Ovarian Cancer Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Metastatic Ovarian Cancer Drug Distributors
  9. 13.2.3 Metastatic Ovarian Cancer Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst